Hemophilia B

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA has approved Rhofade (oxymetazoline hydrochloride) cream, 1%, for the topical treatment of persistent facial erythema associated with rosacea.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.

The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.

The FDA has issued a warning of potential injury and death associated with the use of implantable infusion pumps in the magnetic resonance environment.

The FDA has approved a long-acting opioid painkiller designed to be difficult to crush, manipulate, and abuse.

The FDA has approved a long-acting opioid painkiller designed to be difficult to crush, manipulate, and abuse.

The FDA has approved a long-acting opioid painkiller designed to be difficult to crush, manipulate, and abuse.